Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Posted: Thursday, June 22, 2017

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy plus trastuzumab plus placebo vs chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.